Andreas Hochhaus

89.8k total citations · 18 hit papers
839 papers, 40.0k citations indexed

About

Andreas Hochhaus is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Andreas Hochhaus has authored 839 papers receiving a total of 40.0k indexed citations (citations by other indexed papers that have themselves been cited), including 672 papers in Hematology, 550 papers in Genetics and 282 papers in Rheumatology. Recurrent topics in Andreas Hochhaus's work include Chronic Myeloid Leukemia Treatments (609 papers), Chronic Lymphocytic Leukemia Research (475 papers) and Eosinophilic Disorders and Syndromes (282 papers). Andreas Hochhaus is often cited by papers focused on Chronic Myeloid Leukemia Treatments (609 papers), Chronic Lymphocytic Leukemia Research (475 papers) and Eosinophilic Disorders and Syndromes (282 papers). Andreas Hochhaus collaborates with scholars based in Germany, United States and Italy. Andreas Hochhaus's co-authors include Timothy P. Hughes, Hagop M. Kantarjian, Giuseppe Saglio, Rüdiger Hehlmann, Michele Baccarani, Jörge E. Cortes, Richard A. Larson, François Guilhot, Jerald P. Radich and Nicholas C.P. Cross and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Andreas Hochhaus

800 papers receiving 39.0k citations

Hit Papers

Hematologic and Cytogenetic Responses to Imatinib Mesylat... 2002 2026 2010 2018 2002 2013 2010 2010 2006 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
    2002 1.5k citations Charles L. Sawyers, Andreas Hochhaus et al. profile →
  2. Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
    2013 1.3k citations Andreas Hochhaus et al. profile →
  3. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
    2010 1.2k citations Giuseppe Saglio, Dong‐Wook Kim et al. profile →
  4. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
    2010 1.1k citations Hagop M. Kantarjian, Neil P. Shah et al. profile →
  5. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
    2006 970 citations Hagop M. Kantarjian, Francis J. Giles et al. profile →
  6. Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
    2003 904 citations Timothy P. Hughes, Jaspal Kaeda et al. profile →
  7. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
    2009 890 citations Michele Baccarani, Jörge E. Cortes et al. Journal of Clinical Oncology profile →
  8. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
    2010 807 citations Thomas Ernst, Andreas Reiter et al. profile →
  9. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
    2017 797 citations Andreas Hochhaus, Richard A. Larson et al. profile →
  10. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
    2002 675 citations Andreas Hochhaus, Tanja Lahaye et al. Leukemia profile →
  11. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
    2009 627 citations Andreas Hochhaus, François Guilhot et al. Leukemia profile →
  12. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
    2016 621 citations Jörge E. Cortes, Giuseppe Saglio et al. Journal of Clinical Oncology profile →
  13. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
    2016 563 citations Andreas Hochhaus, Giuseppe Saglio et al. Leukemia profile →
  14. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    2007 540 citations Hagop M. Kantarjian, Francis J. Giles et al. Blood profile →
  15. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.
    2009 444 citations Michael W. Deininger, Stephen G. O’Brien et al. Blood profile →
  16. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
    2011 441 citations Hagop M. Kantarjian, Neil P. Shah et al. Blood profile →
  17. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
    2016 330 citations Michele Baccarani, Andreas Hochhaus et al. Leukemia profile →
  18. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
    2017 320 citations Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andreas Hochhaus Germany 87 30.1k 24.0k 15.6k 7.3k 6.1k 839 40.0k
Moshe Talpaz United States 98 29.2k 1.0× 22.8k 1.0× 13.1k 0.8× 8.7k 1.2× 11.0k 1.8× 778 44.8k
Michele Baccarani Italy 80 20.3k 0.7× 14.6k 0.6× 8.1k 0.5× 5.9k 0.8× 4.9k 0.8× 711 29.1k
Brian Druker United States 106 30.5k 1.0× 21.7k 0.9× 13.5k 0.9× 10.9k 1.5× 17.1k 2.8× 607 54.8k
Giuseppe Saglio Italy 75 18.5k 0.6× 13.4k 0.6× 7.0k 0.4× 4.3k 0.6× 5.6k 0.9× 650 25.0k
John M. Goldman United Kingdom 83 22.2k 0.7× 14.3k 0.6× 8.6k 0.5× 5.1k 0.7× 5.1k 0.8× 496 29.8k
Francis J. Giles United States 105 20.4k 0.7× 15.8k 0.7× 6.3k 0.4× 9.3k 1.3× 15.0k 2.4× 786 41.9k
Ayalew Tefferi United States 115 34.8k 1.2× 38.2k 1.6× 15.9k 1.0× 4.6k 0.6× 22.2k 3.6× 1.1k 54.7k
Susan O’Brien United States 100 21.3k 0.7× 17.3k 0.7× 5.6k 0.4× 7.4k 1.0× 8.3k 1.3× 840 36.5k
Guillermo Garcia‐Manero United States 106 30.6k 1.0× 14.7k 0.6× 4.4k 0.3× 7.5k 1.0× 17.8k 2.9× 1.5k 44.1k
Jerald P. Radich United States 77 16.8k 0.6× 10.1k 0.4× 5.4k 0.3× 3.3k 0.4× 5.0k 0.8× 394 22.0k

Countries citing papers authored by Andreas Hochhaus

Since Specialization
Citations

This map shows the geographic impact of Andreas Hochhaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Hochhaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Hochhaus more than expected).

Fields of papers citing papers by Andreas Hochhaus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Hochhaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Hochhaus. The network helps show where Andreas Hochhaus may publish in the future.

Co-authorship network of co-authors of Andreas Hochhaus

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Hochhaus. A scholar is included among the top collaborators of Andreas Hochhaus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Hochhaus. Andreas Hochhaus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Smith, B. Douglas, Tim H. Brümmendorf, Gail J. Roboz, et al.. (2024). Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study. Leukemia Research. 139. 107481–107481. 1 indexed citations
3.
Deininger, Michael W., Jane Apperley, Christopher Arthur, et al.. (2024). Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.. Journal of Clinical Oncology. 42(16_suppl). 6501–6501.
4.
Hughes, Timothy P., Andreas Hochhaus, Naoto Takahashi, et al.. (2024). ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.. Journal of Clinical Oncology. 42(17_suppl). LBA6500–LBA6500. 2 indexed citations
5.
Rinke, Jenny, et al.. (2023). Molecular‐defined clonal evolution in patients with classical myeloproliferative neoplasms. British Journal of Haematology. 202(2). 308–317. 4 indexed citations
6.
Branford, Susan, Dennis Dong Hwan Kim, Jane F. Apperley, et al.. (2019). Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 33(8). 1835–1850. 84 indexed citations
7.
Schmidt, Thorsten, et al.. (2019). Importance of and Satisfaction with Information about Their Disease in Cancer Patients. Journal of Cancer Education. 35(2). 403–411. 14 indexed citations
8.
Buentzel, Jens, et al.. (2018). The use of complementary and alternative medicine by patients in routine care and the risk of interactions. Journal of Cancer Research and Clinical Oncology. 144(3). 551–557. 48 indexed citations
9.
Franke, Georg‐Nikolaus, Jacqueline Maier, Kathrin Wildenberger, et al.. (2017). Incidence of Low Level Mutations in Newly Diagnosed CML Patients: A Substudy of the German Tiger Trial. Blood. 130. 252. 1 indexed citations
10.
Thielen, Noortje, Johan Richter, Gisela Barbany, et al.. (2016). Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy. Clinical Cancer Research. 22(16). 4030–4038. 14 indexed citations
11.
Cortes, Jörge E., Giuseppe Saglio, Hagop M. Kantarjian, et al.. (2016). Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology. 34(20). 2333–2340. 621 indexed citations breakdown →
12.
Schnetzke, Ulf, et al.. (2013). Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia. Annals of Hematology. 92(8). 1071–1077. 13 indexed citations
13.
Hoff, Paulo M., Andreas Hochhaus, Bernhard C. Pestalozzi, et al.. (2012). Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology. 30(29). 3596–3603. 112 indexed citations
14.
Stein, Andrew M., Dean Bottino, Vijay Modur, et al.. (2011). BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment. Clinical Cancer Research. 17(21). 6812–6821. 32 indexed citations
15.
Burchert, Andreas, Martin C. Müller, Philippe Kostrewa, et al.. (2010). Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology. 28(8). 1429–1435. 120 indexed citations
16.
Hughes, Timothy P., Giuseppe Saglio, Susan Branford, et al.. (2009). Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. Journal of Clinical Oncology. 27(25). 4204–4210. 236 indexed citations
17.
18.
Früehauf, Stefan, Julian Topaly, Eike C. Buss, et al.. (2007). Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 109(8). 1543–1549. 43 indexed citations
19.
Berger, Ute, Ole Maywald, Markus Pfirrmann, et al.. (2005). Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 19(6). 984–989. 54 indexed citations
20.
Fehse, Boris, Klaus Kühlcke, Helmut Renges, et al.. (2001). Real-Time Quantitative Y Chromosome-Specific PCR (QYCS-PCR) for Monitoring Hematopoietic Chimerism after Sex-Mismatched Allogeneic Stem Cell Transplantation. Journal of Hematotherapy & Stem Cell Research. 10(3). 419–425. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Moshe Talpaz Breakdown of academic impact, for papers by Michele Baccarani Breakdown of academic impact, for papers by Brian Druker Breakdown of academic impact, for papers by Giuseppe Saglio Breakdown of academic impact, for papers by John M. Goldman Breakdown of academic impact, for papers by Francis J. Giles Breakdown of academic impact, for papers by Ayalew Tefferi Breakdown of academic impact, for papers by Susan O’Brien Breakdown of academic impact, for papers by Guillermo Garcia‐Manero Breakdown of academic impact, for papers by Jerald P. Radich
Rankless by CCL
2026